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Intra class correlation coefficients between the countries were high: from 0.89 
(England vs. US) through 0.99 (Canada vs. US). ConClusions: This proof of con-
cept study indicates that computer-based choice tasks for the EQ-5D-5L in the 
general population are feasible and parameter of the choice tasks estimates are 
generally consistent and logical, and the estimated values are largely consistent 
between the 4 countries.
PP3
Can the Use of soCial Media and Mobile aPPs iMProve Patient 
Knowledge of disease and health oUtCoMes? a systeMatiC review
Abogunrin S., Martin A.
Evidera, London, UK
objeCtives: The use of interactive social media (SM) based on Web 2.0 technology, 
e.g. Twitter, Facebook, MySpace; and mobile apps, is increasing but its role in improving 
patient knowledge of their disease and its management is unclear. We conducted a 
systematic review to assess the evidence for health benefits from SM. Methods: We 
searched MEDLINE and EMBASE for relevant articles published in the last five years that 
used words synonymous with SM; patient, carer, or parents’ preferences, opinions or 
views; pharmacological interventions; and disease. We included comparative studies 
or systematic reviews on the use of any SM by patients, that measured differences in 
knowledge about disease, uptake of pharmacological interventions, or clinical outcomes 
from better management of disease. Articles were excluded if they reported only the 
use of SM by health care professionals, or if they were case studies, narrative reviews 
or expressed expert opinions. Results: We identified 3,232 unique abstracts, 24 of 
which reported the use of interactive, internet-delivered programs (n= 13), Facebook 
(n= 4), and mobile apps (n= 3) , for improving health outcomes of patients with cancer, 
or inflammatory, mental health, musculoskeletal, neurologic, ophthalmologic, or sexual 
health-related disorders. Patients receiving SM-based interventions showed improved 
knowledge of their disease, and better clinical outcomes compared with controls. Two 
additional studies reported on the use of SM aimed at increasing knowledge, and self-
efficacy in parents of children with cystic fibrosis. Overall, the studies showed that 
SM-based interventions improved knowledge of disease and clinical outcomes com-
pared with control groups. ConClusions: Surprisingly little research has been con-
ducted on the value of SM to aid and support patients. What evidence exists suggests 
that SM tools offer health benefits. fFrther work is needed to confirm these effects and to 
assess how best the tools might increase patients’ knowledge about disease, treatment 
adherence and clinical outcomes.
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objeCtives: To determine the importance of patient reported outcomes (PROs) 
in the reimbursement of orphan drugs in Europe and identify any HTA authority 
preferences for particular PRO measures. Methods: All 31 products assigned an 
orphan designation by the European Medicines Agency (EMA), between January 
2009 and May 2013, were evaluated against the following criteria: approval for 
marketing, submission for reimbursement/price negotiation to NICE, SMC, G-BA, 
and HAS, presence or absence of PROs, approval or rejection of reimbursement 
application. Where available, HTA guidance documents resulting from the appli-
cations were reviewed in detail to determine the impact of PRO measures on the 
reimbursement decision. Results: Of the 31 products assigned an orphan des-
ignation, 26 were granted marketing authorisation by the EMA. Eleven products 
were submitted to NICE for reimbursement in England of which 7 submissions 
contained PROs and 6 were approved. In Scotland, 11 products were submitted for 
reimbursement to the SMC and of the 7 submissions containing PRO data, 3 were 
recommended for reimbursement. One submission is still pending. In Germany, 7 
products were submitted to the G-BA of which 5 contained PROs and were allowed 
to enter into price negotiations. The French HTA authority, HAS, evaluated 20 sub-
missions of which 9 contained PROs and 19 were approved. ConClusions: The 
results of our assessment of EMA approved orphan drugs indicates that a great 
deal of variation exists across Europe with respect to the evaluation of orphan 
drugs for reimbursement or price negotiation. In some countries, reimbursement is 
largely independent of evidence of reported patient benefit while in others, where 
evidence of economic value is critical for success, robust PRO data are essential.
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Cl1
a CoMParison of Methodologies for estiMating sUrvival in Patients 
treated with seCond-generation tyrosine-Kinase inhibitors (tKis) 
for ChroniC Myeloid leUKaeMia (CMl)
Pennington B.1, Batty A.J.1, Clifton-Brown E.2
1BresMed, Sheffield, UK, 2Pfizer Ltd., Tadworth, UK
objeCtives: NICE have previously recommended nilotinib, but not dasatinib, as 
a first-line (TA251) and second-line (TA241) treatment in chronic phase (CP) CML. 
Within these appraisals, different methods were used to estimate overall survival 
(OS). Bosutinib, a potent dual Src/Abl TKI, is undergoing a NICE appraisal in sec-
ond-line or later CML (ID495). The objective is to review the OS methods used and 
assess their impact on cost-effectiveness and recommendations in CML apprais-
als. Methods: We identify the methodologies used for estimating OS in TA241 
and TA251 and investigate the impact of using these to estimate OS for the TKIs, 
including bosutinib, in relapsed/refractory CML. Finally, we consider the implica-
tions of the various methodologies on the cost-effectiveness results and recom-
mendations in previous and future NICE assessments of TKIs for CML. Results: The 
base-case in TA241 used a surrogate relationship between response (MCyR) and OS 
objeCtives: Estimating transition probabilities for Markov models is challenging 
when the effectiveness of the studied intervention is measured using a continuous 
score, and only aggregate data by treatment are available. We developed a Bayesian 
calibration method to estimate transition probabilities and applied it in Parkinson’s 
disease (PD). Methods: A previously published Markov model with health states 
corresponding to Hoehn and Yahr (H&Y) stages was adapted. Patient-level datasets 
were simulated to replicate results of clinical trials for different drugs, using the 
UPDRS scale to assess severity, and transition probabilities were estimated from 
simulated data to provide a reference case. Two calibrations methods were tested for 
obtaining transition probabilities without patient-level data. Firstly, the Solver tool 
of Excel was used, with the mean change in UPDRS score and associated variance as 
targets. Secondly, a Bayesian calibration was implemented in OpenBUGS to estimate 
the posterior distribution of transition probabilities, assuming the change in UPDRS 
score has a normal distribution, with observed mean and variance. All other model 
input parameters were taken from the original model. Results: With simulated 
patient-level data, the incremental cost (IC) was estimated at € -7,015 (95% credibility 
interval: € -23,953; € 5,977) and incremental QALYs (IQ) at 0.455 (0.112; 0.950). With 
calibration using the Solver tool, there was an infinity of solutions resulting in IC 
ranging from € -10,141 to € -8,206 and IQ ranging from 0.422 to 0.473. With calibra-
tion using OpenBugs, the IC was estimated at € -6,852 (€ -24,244; € 6,448) and the 
IQ at -0.448 (0.108; 0.959). ConClusions: Incremental costs and QALYs obtained 
using the Bayesian calibration and analysis of patient-level data were similarly 
distributed. Mean results obtained using the Solver tool were comparable, but no 
statistical distribution around results could be provided. This example suggests that 
the Bayesian calibration is a valid method to derive transition probabilities from 
continuous outcome measures.
Patient PreferenCe stUdies
PP1
a Methodology for PrediCting the iMPaCt of CoPayMents on the 
Utilization of health teChnologies
Sabatelli L.
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objeCtives: Copays (or copayments) for health-technologies, such as pharma-
ceutical products, are used by governments and insurers to prevent moral hazard, 
reduce unnecessary utilization of resources, and contribute to the cost of health 
care. Nevertheless they may also reduce access to necessary care, and the financial 
protection associated with health insurance. In addition, from the perspective of the 
manufacturer, the introduction of copays may determine unexpected and abrupt 
falls in demand. The methodology here presented uses data extracted from surveys 
on product utilization and patient income, prior and after the introduction of copays 
in various countries and regions, to predict the potential impact of copays on the 
demand for a pharmaceutical product in a given country or region. Methods: This 
approach uses multi-level multivariate regressions and a micro-economic model 
of demand (which assumes maximization of utility and preference independence) 
to anticipate changes in utilization (and therefore in demand) as a function of the 
amount of copay charges. Data from a computer simulation were used to test the 
method. Results: A non-linear relationship between copay and drug-consump-
tion, determined by the combined effect of the amount charged and of the average 
population income was identified, predicting changes in aggregate demand and in 
income-specific demand. For instance: if we consider two countries both adopting 
a 1 Euro co-pay charge on a (not easily substitutable) product and whose average 
income differs by 20%, we expect the demand to be almost 3% lower in the country 
with the lower income than in the country with the higher income. ConClusions: 
Under general market assumptions, it is possible to build models that estimate the 
potential impact of copay charges. These models can be used to help design health 
policies and market strategies.
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objeCtives: To investigate the feasibility of choice experiments for EQ-5D-5L 
states using computer-based data collection, and to examine the consistency of 
the estimated parameters values derived after modeling the stated preference 
data across countries in a multinational study. Methods: Similar choice experi-
ments were executed in Canada, England, The Netherlands, and United States 
(US). Interactive software was developed to standardize the format of the choice 
tasks across countries, except for England where face-to-face interviewers were 
used. The choice task required respondents to choose between two sub-optimal 
health states. A Bayesian design was used to generate 200 pairs of states that were 
randomly grouped into 20 blocks. Each respondent completed one block consisting 
of 10 pairs. A main-effect alternative-specific multinomial probit regression model 
was used to estimate regression coefficients and to derive values for each health 
state that capture the relative differences in levels between states. Results: In 
total there were 1775 respondents, at least 400 respondents from each country, 
who completed 17750 paired comparisons, resulting into 35500 assessed health 
states. The mean time to perform one choice task was between 29.2 (US) and 
45.2 (England) seconds. All regression coefficients were statistically significant, 
except level 2 for Usual Activities in The Netherlands (p= 0.51). Three regression 
coefficients with illogical ordering were observed (The Netherlands: level 3 Pain/
Discomfort, England: Level 3 Usual Activities & Pain/Discomfort). Predictions for 
the complete set of 3125 EQ-5D-5L states were similar for the four countries. 
